On June 22, 2017, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan Hycela™. This product is a combination of Genentech’s drug rituximab and Halozyme's hyaluronidase enzyme through Halozymes’s proprietary human ENHANZE® technology. The aim of the combination is changing Rituxan from an intravenously administered product into a subcutaneous (under the skin) injection. The new version Rituxan Hycela is expected to reduce the product’s administration time, save money, and appeal to patients as they consider it a friendlier way of administering drugs.
Rituxan Hycela approval was . . .
This content is for paid subscribers.
Today’s Highlights June 30, 2017